Skip to main content

Table 3 Effect of FBXW7 mutations on drug treatment sensitivity

From: Clinical significance of FBXW7 loss of function in human cancers

Drug

Drug Target

IC50

P-value

 

mut-FBXW7

wt-FBXW7

 

UNC0638

G9a and GLP methyltransferases

24.909

19.849

0.00999

 

KIN001-266

MAP3K8

32.119

20.622

0.0265

 

Temsirolimus

MTOR

0.3013

0.13204

0.0244

 

BIX02189

MEK5, ERK5

97.184

79.736

0.0232

 

Tubastatin A

HDAC1, HDAC6, HDAC8

149.28

108.77

0.0254

 

Shikonin

not defined

1.4784

0.94584

0.0109

 

KIN001-042

GSK3B

114.01

89.295

0.0477

 

THZ-2-49

CDK9

36.568

11.993

0.0246

 

KIN001-042

GSK3B

114.01

89.295

0.0289

 

JAK1_3715

JAK1

109.83

79.93

0.0394

 

Tanespimycin

HSP90

0.93356

0.45133

0.0261

 

OSI-930

KIT

77.599

60.839

0.0325

 

AICA

Ribonucleotide

AMPK agonist

3268.4

2217.1

0.0349

 

Venetoclax

BCL2

9.8217

9.1615

0.0209

 

WEHI-539

BCL-XL

35.43

34.404

0.0263

 
  1. This table list drugs with resistance caused by FBXW7 mutations adapted from the GDSC database (https://www.cancerrxgene.org/). The name of the drug is listed along with the pathway targeted. Only data with P values of less than 0.05 were considered
Back to article page

Molecular Cancer

ISSN: 1476-4598